- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 89,760 | 27.05.24 17:45:06 | +0,110 | +0,12% | 0,000 | 0,000 | 89,340 | 89,760 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 904,600 | 27.05.24 09:15:33 | -6,200 | -0,68% | 0,000 | 0,000 | 910,800 | 904,600 |
